• Reversine (A3760): Technical Guide for Aurora Kinase Inhibit

  2026-07-14

  Reversine is a small molecule inhibitor targeting Aurora kinases A, B, and C, enabling precise disruption of mitotic progression for cancer biology research. This guide details practical parameters and workflow setup for reliable use in studies of cell cycle regulation and checkpoint control. Reversine is not intended for diagnostic or therapeutic applications.

• Mecamylamine Hydrochloride: Bridging Gut-Brain Science to Tr

  2026-07-14

  Explore how mecamylamine hydrochloride, a potent nAChR antagonist, is unlocking the mechanistic underpinnings of gut-brain signaling and advancing neuropsychiatric disorder research. This thought-leadership article provides mechanistic clarity, protocol guidance, and strategic insights for translational researchers seeking to leverage cholinergic pathways in models of epilepsy, depression, and beyond. Drawing on landmark findings in microbiota-mediated seizure control, the article positions APExBIO’s mecamylamine as a tool of choice for dissecting complex neural circuits and accelerating the next wave of therapeutic discovery.

• ERK Inhibition Mitigates Autophagy and Mitochondrial Dysfunc

  2026-07-13

  Yuan et al. (2023) reveal that ERK inhibition reduces autophagy and mitochondrial fragmentation, protecting SH-SY5Y neuronal cells from oxygen-glucose deprivation/reoxygenation (OGD/R) injury. Their mechanistic insights into the ERK–Drp1/Mfn2–autophagy axis provide a foundation for new strategies in neuroprotection and experimental modeling of ischemia-reperfusion injury.

• Novobiocin: Aminocoumarin Antibiotic Workflows Refined

  2026-07-13

  Novobiocin stands out for its dual targeting of bacterial DNA gyrase and Hsp90, enabling robust antibacterial, antiparasitic, and antiviral applications. This article distills experimental workflows, troubleshooting strategies, and cross-domain insights to maximize reproducibility and scientific impact.

• Monomeric Amyloid Beta Modulates Microglia in Brain Developm

  2026-07-12

  A recent eLife study demonstrates that monomeric Amyloid Beta-Peptide (1-40) (human) activates a novel signaling pathway in microglia, regulating their function during neocortical development. These findings illuminate an underappreciated physiological role for amyloid beta in neurodevelopment and provide new context for interpreting its depletion and aggregation in Alzheimer’s disease.

• JSH-23: NF-κB Inhibitor for Precision Inflammation Research

  2026-07-10

  JSH-23 empowers researchers to dissect the NF-κB signaling pathway with high selectivity, enabling targeted investigation of inflammation mechanisms in both cell-based and animal models. Its unique mechanism and robust solubility profile make it an essential tool for advanced cytokine regulation studies and translational disease modeling.

• Plk1 Regulation of p31comet in Mitotic Checkpoint Complex Di

  2026-07-09

  This study uncovers how Polo-like kinase 1 (Plk1) modulates the activity of the Mad2-binding protein p31comet during mitotic checkpoint complex (MCC) disassembly, a process essential for accurate chromosome segregation. The findings provide molecular detail on checkpoint regulation, with implications for understanding cell cycle fidelity and potential translational research avenues.

• CCK-8 Modulates Anxiety via Endogenous Opioid Pathways in Mo

  2026-07-09

  This study demonstrates that cholecystokinin octapeptide (CCK-8) alleviates anxiety-like behaviors in morphine-withdrawal rats by upregulating endogenous opioids through CCK1 receptor activation. The findings offer mechanistic insight into the interplay between neuropeptides and the opioid system, suggesting new targets for addiction-related affective disorders.

• MK-2206 dihydrochloride: Precision Workflows in Cancer and A

  2026-07-08

  MK-2206 dihydrochloride is a nanomolar-selective PI3K/Akt/mTOR signaling pathway inhibitor that transforms apoptosis assays and disease modeling. This article delivers actionable workflows, troubleshooting insights, and evidence-based protocol optimizations for researchers leveraging MK-2206 in cancer, metabolic, and bone disease studies.

• (R,S)-Anatabine (C4859): Reliable Solutions for Alzheimer’s

  2026-07-08

  (R,S)-Anatabine (SKU C4859) delivers reproducible, data-backed solutions for researchers investigating amyloidogenic processing and neuroinflammation in Alzheimer’s disease. This scenario-driven guide addresses common experimental challenges and details how APExBIO’s high-purity formulation supports sensitive, reliable, and cost-effective workflows in both in vitro and in vivo models.

• Capecitabine: Tumor-Targeted Prodrug for Preclinical Oncolog

  2026-07-07

  Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) is a tumor-selective fluoropyrimidine prodrug that enables precise modeling of apoptosis induction via Fas-dependent pathways in advanced preclinical oncology research. Its enzymatic activation within tumor tissues underpins its selectivity, as validated in assembloid and xenograft models. APExBIO supplies high-purity Capecitabine for robust, reproducible tumor-targeted drug delivery studies.

• MLN2238: Proteasome β5 Subunit Inhibitor for Advanced Resear

  2026-07-07

  MLN2238 enables precise and robust chymotrypsin-like proteasome inhibition for oncology and proteotoxic stress studies, even in bortezomib-resistant models. Learn how to optimize workflows, troubleshoot solubility challenges, and leverage the latest mechanistic insights to elevate your research.

• Palmitic acid (Hexadecanoic Acid): Technical Parameters & Us

  2026-07-06

  Palmitic acid (SKU N2456) provides researchers with a high-purity, well-characterized saturated long-chain fatty acid for reproducible studies in lipid metabolism, metabolic disorder research, and protein palmitoylation. It is not suitable for protocols that require aqueous solubility or long-term solution storage, requiring careful handling and protocol adherence for optimal results.

• CHI3L1 Inhibition Restores Amyloid Clearance in AD Astrocyte

  2026-07-06

  The referenced study demonstrates that Compound Z17 (CHI3L1-IN-5) restores amyloid-beta clearance and lysosomal function in human astrocytes by selectively inhibiting CHI3L1 and suppressing NF-κB signaling. These findings establish Z17 as a valuable tool for investigating and modulating neuroinflammatory pathways implicated in Alzheimer’s disease.

• DiscoveryProbe™ L1023: Scenario-Driven Reliability in Cancer

  2026-07-05

  This article addresses real-world laboratory challenges in cell-based assays and drug discovery, demonstrating how DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) enables reproducible, high-throughput screening of anti-cancer agents. By integrating scenario-based Q&A and evidence from peer-reviewed literature, it provides actionable guidance for leveraging SKU L1023’s validated compound selection and workflow compatibility.

16165 records 1/1078 page Next 12345 下5页 Last page